# KPV

Anti-inflammatory alpha-MSH fragment for gut, skin and allergy inflammation; animal data only.

- Page: https://peprank.xyz/peptides/kpv
- Category: Gut (Research peptide)
- Also known as: Lys-Pro-Val; alpha-MSH C-terminal tripeptide; part of 'KLOW' blend
- Routes: Oral / Topical / Injection
- Sequence: KPV (α-MSH 11-13; often N-acetyl or C-amide)
- Safety tier: Strict: Caution · Balanced: Caution · Evidence only: Caution
- Risk axes (0 none to 3 severe): Seen harm 1, Mechanism 1, Data gap 3, Silent harm 1, Product 3
- Positive: 59% of 48 graded reports glowing or positive, shrunk toward the 49% all-report average by 8 reports' weight
- Rank: #1 of 61 research peptides
- Graded reports: 48 (Glowing 12, Positive 17, Mixed 4, Nothing 6, Negative 5, Bad reaction 4)
- Evidence: Animal only — Mouse colitis models via PepT1 uptake; no human trials
- Access: Grey market
- Onset: 1-3 days for allergy, reflux or itch relief in responders; 2-4 weeks for skin and joints
- Lasts: cumulative; several users relapse within about two weeks of stopping
- Cost per month: ≈ €31–61 (at 250–500 mcg/day, Semax Polska at €4.10/mg)
- Dose users report: 250–500 mcg/day (median 350 mcg, n=11)
- Updated: 2026-10-30

## What users report

About half of users report a clear benefit, much of it from KPV on its own rather than only inside the KLOW blend: eczema, acne, psoriasis and rosacea clearing, better tolerance of trigger foods in MCAS and colitis, less joint pain, and some striking seasonal-allergy reports. Several relapse within about two weeks of stopping. Around 15% feel nothing, and oral capsules are named most often by those who did. Roughly a quarter end up net worse in the first one or two weeks, with flu-like symptoms, dizziness, gas and diarrhoea, or mood swings. Starting at 50-100 mcg usually avoids this. A few report a rash or a severe migraine.

**Effects:** less body-wide inflammation / aches; eczema, psoriasis, dandruff improvement; calmer gut / IBD symptoms; fewer seasonal allergy symptoms

**Downsides:** flu-like or cold-like feeling first days; fatigue; bloating, gas, diarrhoea; occasional light-headedness

**Risks:** No human exposure data at all (FDA note); long-term effects unknown; Generic: grey-market purity

**Typical use:** 250-500 mcg/day subQ or 500-1000 mcg oral on an empty stomach; sensitive users start at 50 mcg. HHS enforcement discretion (29 Oct 2026) covers oral/topical KPV only.

**Getting it:** Mostly research-chemical vials and oral capsules online; HHS now lets pharmacies compound oral and topical KPV.

**Stacked with:** KLOW (GHK-Cu + BPC-157 + TB-500 + KPV) (The most common way people take it, mainly for skin and old injuries, which makes KPV's own share hard to separate.); BPC-157 (Paired for gut and joint inflammation; a few users found BPC-157 did more, or eased KPV's early 'off' feeling.); GHK-Cu (Two-peptide skin stack (or KLOW without BPC/TB) for eczema, rosacea and acne.)

## Risk profile

- **Seen harm 1/3:** No human study exists. Among about fifty first-hand reports, one describes an emergency visit for migraine and others a spreading rash or chest tightness; isolated.
- **Mechanism 1/3:** The C-terminal tripeptide of alpha-MSH, anti-inflammatory through NF-kB in mouse colitis without acting on melanocortin receptors; dampening inflammation is a speculative rather than demonstrated harm path.
- **Data gap 3/3:** FDA found no human exposure data by any route, and there is no published trial or pharmacokinetic study.
- **Silent harm 1/3:** Reported effects (GI upset, dizziness, rash, headache) appear within days.
- **Product 3/3:** Mostly grey-market vials, injected, with oral capsules a common alternative; HHS let pharmacies compound oral and topical KPV only from October 2026.
- **Never if:** Pregnancy or breastfeeding (no human reproductive data)

## Top reports

- Glowing, immune: “About 5 weeks on KPV – have not missed a day. It’s been a week since my last sneeze attack – usually have several a day.” — [@lakemandude on X](https://x.com/lakemandude/status/2110858732263612663)
- Glowing, immune, 500 mcg: “Notes after two doses of 500mcg KPV for MCAS: - Significant brain fog improvement - Significantly less dizzy - Have laughed out loud multiple times (basically non-existent before)” — [@rileyanderz on X](https://x.com/rileyanderz/status/2058249881962086540)
- Glowing, skin-hair: “After about a month or less I stopped getting any acne, and now maybe 3-4 months later I still had not gotten any acne and I’ve even taken breaks of kpv of up to two weeks and it still stayed” — [r/Biohackers](https://www.reddit.com/r/Biohackers/comments/1to8f07/kpv_fixed_my_acne_permanently/)
- Glowing, skin-hair, 500 mcg/day: “After those initial 3 days my skin stopped itching and then the inflammation and redness started to drastically decrease day after day. So far my skin has repaired to around 70% of it's original state” — [r/Biohackers](https://www.reddit.com/r/Biohackers/comments/1pimq9p/kpv_peptide_cycle_update/)
- Glowing, immune, 250 mcg/day for 3 weeks, then 500 mcg/day: “I started taking KPV and no joke within the first two days of taking it, I had zero ear congestion and it has not come for a visit since. I have never had something so successful for this.” — [r/Biohackers](https://www.reddit.com/r/Biohackers/comments/1s69j21/how_effective_is_kpv_peptide_is_it_really_worth_it/ookiknb/)

## Cheapest in Europe

- [XL Peptides](https://xlpeptides.com/product/kpv-10mg/) (GB): KPV 10mg Research Peptide, €29, €2.87/mg
- [Baltic Peptides](https://balticpeptides.com/product/kpv/) (LT): KPV 10mg, €35, €3.50/mg
- [Semax Polska](https://semaxpolska.com/en/kpv-10-mg/) (PL): KPV 10 mg, €39, €3.87/mg (also contains 5 mg GHK-Cu, judged as [GHK-Cu (injectable)](https://peprank.xyz/peptides/ghk-cu-injectable) since the nasal route is systemic: Strict Avoid · Balanced Avoid · Evidence only Caution)
- [Condor Research](https://condorresearch.com/product/kpv-capsules/) (SK): KPV Capsules 60 x 500mcg, €120, €4.00/mg
- [Semax Polska](https://semaxpolska.com/en/kpv-10mg-woda-bakteriostatyczna/) (PL): KPV 10mg + bacteriostatic water, €41, €4.10/mg

## Studies

- [PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Gastroenterology)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/) (animal, 2008): Oral KPV in drinking water reduced DSS and TNBS colitis in mice via uptake through the PepT1 transporter.
- [Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease](https://academic.oup.com/ibdjournal/article/14/3/324/4653598) (animal, 2008): KPV cut weight loss and colon inflammation in DSS and T-cell-transfer colitis, even in mice lacking a working MC1 receptor.
- [Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis](https://pmc.ncbi.nlm.nih.gov/articles/PMC5498804/) (animal, 2017): Nanoparticle-encapsulated oral KPV sped mucosal healing and lowered inflammation in mouse colitis.
- [Alpha-MSH and related tripeptides: biochemistry, anti-inflammatory and protective effects in vitro and in vivo (Endocrine Reviews)](https://pubmed.ncbi.nlm.nih.gov/18612139/) (review, 2008): Summarises cell and animal data showing KPV dampens NF-kB-driven inflammation in skin, gut and eye models; no human trials.

## Sources

- [Dalmasso et al., PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Gastroenterology 2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/)
- [FDA risk note: no human exposure data for KPV](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)
- [HHS enforcement discretion for 6 peptides: routes and conditions (Drug Topics, 29 Oct 2026)](https://www.drugtopics.com/view/hhs-lets-pharmacies-compound-peptides-as-fda-writes-official-rule)